Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PATENTS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,045 records · Page 58Linked to original sources
PubMed1994

Protection of the patent internal mammary artery by-pass graft from subsequent sternotomy.

OBJECTIVE: We describe a technique to protect the patent internal mammary artery graft from injury by repeat sternotomy. INTERVENTIONS: The internal mammary artery is dissected as far proximally as possible. The left pleural space is opened widely thus allowing the left lung to protrude through the pleural defect once mechanical ventilation is resumed. The left lung is then interposed between the internal mammary graft and the sternum. The internal mammary artery is thereby protected from adherence to the sternum and injury upon resternotomy. RESULTS: In two patients in whom this technique was employed repeat sternotomy was easily performed without injury to the internal mammary artery. CONCLUSIONS: This simple technique effectively protects the patent internal mammary artery bypass graft from injury at subsequent sternotomy.

Humans↗
PubMed1975

[Practice of patenting microbiological objects in foreign countries].

Data on the main objects corresponding to the inventions in the field of microbiology and microbiological industry acceptable for patenting abroad are presented. Examples of claims for each type of the protected objects taken from patents filed in main capitalist countries are given. The examples have necessary comments.

Anti-Bacterial Agents↗
PubMed1994

A patent internal mammary artery graft decreases the risk of reoperative coronary artery bypass surgery.

In order to evaluate the potential risks of a patent internal mammary artery bypass at reoperative coronary artery bypass grafting, we have reviewed the records of 233 consecutive patients undergoing reoperative coronary artery bypass grafting between 1 January 1991 and 31 December 1993, including 209 patients having an occluded mammary graft or no mammary graft (Group I) and 24 patients having a patent mammary graft (Group II). With regard to preoperative patient characteristics, the only significant differences between the groups were: Group II patients had a higher preoperative left ventricular ejection fraction than did Group I patients (63.7% +/- 8.9% vs. 52.1% +/- 10.1%, p < 0.001); and Group II patients had received fewer grafts per patient than had patients in Group I (2.2 +/- 1.1 vs 3.6 +/- 1.4 grafts per patient, p < 0.001). There were no entry injuries to the grafts or to the heart in either of the groups. No perioperative mortality was encountered in Group II, while 11 patients died in Group I (p < 0.05). Group II had a significantly higher incidence of reexploration for post-operative bleeding, whereas Group I had a significantly higher incidence of low postoperative cardiac output. The incidence of all other perioperative complications did not differ between the groups. The results of this study support the use of mammary grafts even in patients who are likely to need repeat coronary artery bypass grafting and certainly does not disqualify such patients from a 2nd operation.

Coronary Artery Bypass↗
PubMed1993

Fatal asthma attributed to patent foramen ovale.

A 37 year old woman was admitted to the hospital with acute severe asthma, shortly followed by respiratory failure and circulatory arrest. Despite intensive cardio-pulmonary resuscitation, during which extreme arterial hypoxaemia persisted, the patient died. Postmortem examination revealed a patent foramen ovale, with a diameter of 1 cm. A severe right-to-left shunt, initiated by acute pulmonary hypertension, was considered to be the cause of death. Because of the relatively high prevalence of patent foramen ovale in the normal population, we suggest this patency may enhance the risk of fatal outcome of acute severe asthma.

Adult↗
PubMed1994

[A case of paradoxical cerebral embolism through a patent foramen ovale diagnosed by necropsy].

A 62-year-old man was admitted to our hospital for disturbed consciousness and left-side motor sensory deficit. His blood pressure was 142/100 mmHg and an electrocardiogram was normal. CT of the brain revealed a low density area in the distribution of the right middle cerebral artery (MCA). Cerebral angiography demonstrated occlusion of the right internal carotid artery and an embolus. We diagnosed cerebral embolism, but we could not detect source of embolism. His condition deteriorated rapidly, and he died four days later. At necropsy, an elongated piece of thrombus 10 cm in length was lodged in a patent foramen ovale lying in each atrium. No other thrombus was seen in the heart, the myocardium and coronary arteries were normal. Both main pulmonary arteries contained thrombus. The lungs showed edema and congestion. There was no thrombus of both common iliac veins. The right internal carotid artery was occluded at its bifurcation by embolus, distal to which the cavernous segment was 7 cm filled with clot. We reported a rare paradoxical cerebral embolism through a patent foramen ovale diagnosed by necropsy. If no left-sided circulatory source can be demonstrated, the possibility of a paradoxical embolism should be considered.

Heart Septal Defects, Atrial↗
PubMed1993

Arterial gas bubbles after decompression in pigs with patent foramen ovale.

With patent foramen ovale (PFO), thought to be a risk factor for some forms of DCS, venous bubbles may pass through the patent opening to become arterial bubbles. We exposed 14 anesthetized, spontaneously breathing pigs to air at 5 bar (500 kPa, absolute pressure) for 30 min and then rapidly decompressed at 2 bar/min to 1 bar. We measured intravascular pressures, blood gases, and, with transesophageal echocardiology, bubbles in the pulmonary artery and ascending aorta. Autopsy showed that six of the pigs had a PFO. Arterial bubbles occurred more frequently in the PFO group (in six out of six) than in the non-PFO group (in two out of eight, P < 0.01). When arterial bubbles were detected, the venous bubble count and the pulmonary artery pressure tended to be lower in pigs with PFO than in pigs without a PFO. We conclude that a PFO increases the risk of arterial bubbles after decompression.

Animals↗
PubMed1996

Heart transplantation complicated by a patent foramen ovale of the recipient atrial septum.

A patent foramen ovale after heart transplantation is a relatively uncommon occurrence. We report a case of a 58-year-old man with profound hypoxemia after orthotopic cardiac transplantation for end-stage ischemic cardiomyopathy. Transesophageal echocardiography demonstrated the presence of a patent foramen ovale in the recipient atrial cuff. Primary closure was performed with correction of the right-to-left shunt.

Echocardiography, Transesophageal↗
PubMed1994

[Coronary artery bypass surgery-redo operation particularly in patients with a functioning ITA graft or with a patent atheromatous vein graft].

An experience with redo-CABG in 20 patients is described. The incidence of reoperation in patients undergoing primary CABG in our hospital was 1.4%, relatively low even in Japanese population. The low incidence of redo-CABG in our hospital depends on the relatively short period of follow-up of 14 years, the prevalence of interventional cardiology and the early routine use of ITA grafts. The main cause of reoperation was the failure of a SVG to the LAD in 70 to 80% of the cases. The most important and difficult decision-making in redo-CABG is the selection of surgical approaches and cardioprotective methods in patients with a patent functioning ITA graft, and the management of an atherosclerotic patent SVG. Surgical strategies in these situations are discussed.

Adult↗
PubMed1998

Factors associated with limb loss despite a patent infrainguinal bypass graft.

Lower-extremity limb salvage should parallel infrainguinal bypass graft patency. To determine factors associated with limb loss despite a patent bypass, we reviewed 191 consecutive infrainguinal bypasses in 158 patients followed prospectively over 42 months. In this series of 176 (92%) vein grafts, 15 (8%) expanded polytetrafluoroethylene grafts, 122 (64%) tibial artery bypasses, and 170 (89%) bypasses placed for limb salvage, 29 major lower-extremity (above-knee or below-knee) amputations were performed in 29 patients, 12 because of ischemia after graft thrombosis and 17 (9% of series) due to progression of soft tissue infection/necrosis despite a functioning bypass. Primary and secondary 36-month vein graft patencies by life-table analysis were 61 per cent and 81 per cent, respectively. When the 17 cases of limb loss were compared to the rest of the series, nonstatistically significant variables included male sex [11 (65%) vs 79 (56%); P = 0.608] and diabetes [12 (71%) vs 80 (57%); P = 0.310]. Statistically significant variables included black race [9 (53%) vs 39 (28%); P = 0.048]; chronic renal failure [6 (35%) vs 12 (9%); P = 0.005], placement to a tibial/pedal artery [15 (88%) vs 107 (62%); P = 0.034], distal anastomosis to the anterior tibial/dorsalis pedis (AT/DP) artery [8 (47%) vs 27 (16%); P = 0.004], and grafts requiring late revision [7 (41%) vs 22 (13%); P = 0.006]. Thirteen (76%) extremities had an intact pedal arch. Nine amputations were performed within 30 days (early group), and eight were performed from 45 days to 20 months (median, 8 months) after bypass placement (late group). The most common primary causes of limb loss in the early group were overwhelming progression of soft-tissue infection despite patent bypass (n = 4; 44%) and insufficient runoff in the foot (n = 3; 33%). In the late group, amputation most often followed long treatment of a chronic proximal diabetic neuropathic foot ulcer with osteomyelitis. Five (63%) grafts in this group were anastomosed to the AT/DP arteries. These data suggest that patients with chronic renal failure, chronic neuropathic heel ulcers, and an AT/DP bypass are at greater risk for amputation despite a working bypass, especially if the graft develops a hemodynamically significant stenosis. Careful judgment and patient selection under these circumstances are thus justified.

Adult↗
PubMed1998

Patent foramen ovale and pulmonary embolism. An underestimated co-morbidity following cardiac surgery.

When pulmonary embolism occurs in the presence of a patent foramen ovale the sudden increase in the right heart pressure can open the defect and could cause right to left atrial shunting. This may further aggravate the already existing hypoxemia, and the direct communication between the venous and the arterial circulation increases the risk of paradoxical embolization. In this paper we present a case of postoperative pulmonary embolization in a patient with patent foramen ovale, and the effects of these co-existing conditions are reviewed. In the cardiac surgical literature such a complication has not yet been described.

Aged↗
PubMedDate not supplied

[Identification of sentinel lymph node with patent blue V in patients with cutaneous melanoma].

Regional lymphadenectomy in patients with cutaneous malignant melanoma in stages I-U AJC/UICC has not demonstrated improvement either in loco-regional control or in survival. The results of the lymphatic mapping technique have demonstrated that on identifying the sentinel node, the group of patients with microscopic nodal metastases can be selected for regional treatment. We performed the intraoperative lymphatic mapping technique with 1 ml of blue patent V by intradermal injection just around the primary melanoma; after injecting the dye we incised the nodal skin region, identifying the sentinel node by its blue color. The histologic examination, by frozen section of this node, determines whether or not to proceed with a formal lymphadenectomy. We calculated the sensitivity of the dye for the identification of the sentinel node and the Pearson's test was performed between the intraoperative histologic study and the definite pathological result. Thirty one lymphatic mappings were performed in 29 patients with stages I-II malignant cutaneous melanoma. The sentinel node was found in 26/31 explored lymphatic zones, and in 5, it was not found, sensitivity of 84%; 23/26 sentinel nodes were negative and only 3/26 were metastatic in frozen section. The Pearson's test result was 0.78 with a predictive value of 92%. The blue patent V intraoperative lymphatic mapping technique in patients with malignant cutaneous melanoma provided a great sensitivity to identify the sentinel node and allows the identification of patients with high risk of microscopic nodal metastases.

Adult↗
PubMed1977

The atrial septal defect-patent ductus arteriosus complex.

Both atrial septal defect and patent ductus arteriosus are common isolated lesions, each accounting for approximately 10% of the total incidence of congenital heart diseases. Yet, the combination of these defects, without other significant cardiac lesions, is infrequent. We review the clinical and pathologic data on 16 patients with this combination of defects, including cardiac catheterization data on eight patients. In patients with this combination, we found an unusually high incidence of severe pulmonary hypertension, multiple noncardiac anomalies, mental retardation, and early mortality.

Abnormalities, Multiple↗
PubMed1981

Furosemide use in premature infants and appearance of patent ductus arteriosus.

Furosemide is a known stimulant of the renal release of prostaglandin E2, a potent dilator of the ductus arteriosus. A possible relationship between furosemide use in infants with respiratory distress syndrome (RDS) and the incidence of patent ductus arteriosus (PDA) was investigated using two different retrospective analyses. The amount of furosemide administered prior to the day a murmur was heard in the infants with PDA was higher than the amount given to patients without PDA during the same period. In a historical analysis of patients treated for RDS in the years 1970 through 1979, furosemide use and fluid intake appeared to be independent factors contributing to the incidence of PDA. The proposed relationship between furosemide use and the occurrence of PDA in patients with RDS warrants further study.

Ductus Arteriosus↗
PubMed1982

Preschool assessment of infants with a patent ductus arteriosus: comparison of ligation and indomethacin therapy.

We report the preschool growth and development of preterm infants with problematic patent ductus artferiosus requiring either surgical ligation or indomethacinn treatment in the neonatal period. Of 60 who completed longitudinal growth assessments, no differences in growth to 3 years could be demonstrated except for four cases of regressed retinopathy of prematurity among the ligated infants. Developmental tests (Bayley Scales of Infant Development and the Peabody Picture Vocabulary Test) showed no group differences at preschool ages. Although psychomotor performance on the Bayley Scales in the first 1 1/2 years was significantly lower among the surgically treated infants, later analysis showed that a similar number in both treatment groups scored within the normal range. No selective short- or long-term adverse effects of indomethacin treatment could be demonstrated.

Body Height↗
PubMed1982

Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one-year follow-up.

Fifty-five infants participated in a double-blind study of indomethacin therapy for the closure of patent ductus arteriosus. Seventeen infants died. There was no significant difference in autopsy findings between the groups with respect to pneumonia, disseminated intravascular coagulopathy, necrotizing enterocolitis, sepsis, intraventricular hemorrhage, hydrocephalus, kernicterus, brain softening, and renal damage. For those infants who survived and returned for follow-up at approximately 1 year of age, there was no significant difference between the control (n = 17) and indomethacin (n = 13) groups with respect to physical growth, Bayley scores, respiratory infection, abnormal eye ground, neurological defects, and abnormal EEG. Four in the control group (24%) and three in the indomethacin group (23%) had moderate to severe neurological defects and/or scored less than 80 on the Bayley Mental Development Index or Psychomotor Development Index. It appeared that indomethacin therapy did not have a long-term adverse effect on premature infants.

Double-Blind Method↗
PubMed1982

Parenteral indomethacin for closure of the patent ductus arteriosus. Clinical experience with 67 preterm infants.

During a 19-month period, 23% of preterm infants had symptomatic patent ductus arteriosus (PDA). Intravenous indomethacin was administered to 67 infants with successful closure in 91% of the patients and in 83% of those with birth weights less than 1,000 g. No differences were found between the number of doses required and birth weight, gestational age, or age at initial therapy. Transient alterations in renal function were common after therapy, but mild renal failure occurred in only four infants. The incidence of intraventricular hemorrhage and necrotizing enterocolitis in treated infants was similar to that in the total preterm population. Cicatricial retrolental fibroplasia developed in one patient. Bronchopulmonary dysplasia occurred more frequently in infants with PDA, but a decreased incidence was found after early ductal closure. Intravenous indomethacin administration successfully effects ductal closure without major complications in preterm infants.

Age Factors↗
PubMed1987

Response of the patent ductus arteriosus to indomethacin treatment.

The purposes of this study were to examine the response of the patent ductus arteriosus (PDA) to indomethacin, using serial two-dimensional and pulsed Doppler echocardiographic studies, and to correlate the response to treatment with serum indomethacin levels. Nineteen preterm infants (gestational age, 26 to 31 weeks [mean, 28 weeks]; weight, 600 to 1680 g [mean, 1060 g]) were treated with indomethacin. Two-dimensional and pulsed Doppler echocardiograms were obtained before administration of indomethacin and daily thereafter until the day after the last dose. Ductal responses to treatment were graded as open, constricted, or closed, and serum indomethacin levels were obtained 24 hours after the last dose. The PDA initially closed in 11 (58%) of 19 infants; however, in four of the 11, PDA reopened and three of four required surgical ligation. In seven (37%) of 19 patients, the PDA initially constricted, but five of seven subsequently reopened and required ligation. In one patient, indomethacin had no effect on the PDA. The mean indomethacin level for the whole group was 622 ng/mL. There was no difference in indomethacin level between the group with initial closure vs those with constriction (580 vs 590 ng/mL), nor between those who eventually required ligation and those who did not. This study demonstrates that the majority of premature infants respond to indomethacin treatment with ductal constriction or closure but that reopening occurs frequently. The initial response does not mean that the ductus will remain constricted or closed, and surgical intervention may still be necessary. A serum indomethacin level of more than 250 ng/mL does not ensure ductal closure.

Drug Evaluation↗